CPIG
CLDX icon

Chicago Partners Investment Group’s Celldex Therapeutics CLDX Stock Holding History

Chicago Partners Investment Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-32
Closed -$2K – 954
2017
Q2 		$2K Buy
+32
New +$1.42K ﹤0.01% 621

Other funds holding CLDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Chicago Partners Investment Group's CLDX Position: Q3 2017 in Review

Chicago Partners Investment Group sold out of Celldex Therapeutics (CLDX) in Q3 2017, closing a stake of 32 shares — an estimated $2K sold.

Chicago Partners Investment Group first reported a position in CLDX in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 129 funds tracked by Wall St. Rank hold CLDX as of Q3 2017.

  • Chicago Partners Investment Group reported no remaining Celldex Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Chicago Partners Investment Group sold 32 Celldex Therapeutics shares in Q3 2017, an estimated $2K.
  • Chicago Partners Investment Group first reported a position in Celldex Therapeutics in Q2 2017 and held it in 1 quarter.
  • Chicago Partners Investment Group's Celldex Therapeutics position peaked at $2K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2017.

Based on Chicago Partners Investment Group's 13F filing for Q3 2017, filed 22 Nov 2017.